SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis
A survey-based study analyzed vaccination reactions and disease deterioration after SARS-CoV-2 vaccination among more than 6,000 MS patients in Germany and the United Kingdom.
Read More »
Multiple Sclerosis (MS)
Multiple Sclerosis (MS) involves communication problems between the brain and the rest of the body due to immune attacks on axons and myelin in the central nervous system. Below are COVID news and research updates that specifically relate to MS.
COVID-19 Outcomes in Myasthenia Gravis Patients
Symptoms related to COVID-19 infections such as systemic inflammation, neurological complications, and a dysregulated immune response can lead to worse clinical outcomes for patients with Myasthenia Gravis (MG). Researchers conducted an observational retrospective study to measure COVID-19 outcomes in these patients, especially in regard to exacerbation of MG symptoms.
Read More »Assessing the Safety of mRNA COVID-19 Vaccination in the Immunocompromised
In a research article published yesterday in Frontiers in Oncology, COVID-19 vaccine (Pfizer and Moderna) safety was evaluated in a population of 566 immunocompromised patients including those with hematological malignancies (131), solid tumors (191), immune-rheumatological diseases (86), and neurological disease (158) including multiple sclerosis and generalized myasthenia.
Read More »Covid-19 Outcomes in Autoimmune Disease Patients
Autoimmune disease is currently considered a risk factor for severe COVID-19. A research article published in Rheumatology last Fall summarized 30-day outcomes of autoimmune disease (AD) patients following hospitalization with COVID-19. AD patients diagnosed and/or hospitalized between January and June 2020 with COVID-19 were included, and their 30 day outcomes were compared to patients with at least one AD hospitalized with influenza from September 2017 through April 2018.
Read More »